-- FDA sets updated PDUFA goal date of March 20, 2026 –
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Seeking Alpha / 9 hours ago 3 Views
Seeking Alpha / 9 hours ago 3 Views
-- FDA sets updated PDUFA goal date of March 20, 2026 –
Comments